{"@id":"https://bioecon.ru/technology/in-vivo-car-t-generation/","@type":"Technology","cluster":"regenerative-personalized","formats":{"html":"https://cn.bioecon.ru/technology/in-vivo-car-t-generation/","json":"https://cn.bioecon.ru/api/v1/technology/in-vivo-car-t-generation/index.json"},"id":"in-vivo-car-t-generation","industries":["pharma","biomanufacturing"],"lang":"cn","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/agc-biologics/","https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/impextraco/","https://bioecon.ru/companies/impacfat/","https://bioecon.ru/companies/host-group/","https://bioecon.ru/companies/esco-aster/","https://bioecon.ru/companies/biobichos-ltda/","https://bioecon.ru/companies/allozymes/","https://bioecon.ru/companies/naturmega/","https://bioecon.ru/companies/brevel/","https://bioecon.ru/companies/checkerspot/"]},"maturity":7,"name":"体内原位CAR-T编程工程化技术","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"T细胞表面特异性趋向工程改造"},{"n":2,"title":"肝脏巨噬细胞非特异性清除规避"},{"n":3,"title":"mRNA瞬时受控与慢病毒永久整合双轨策略"},{"n":4,"title":"体内微剂量嵌合细胞因子同步激活"}],"summary":"通过静脉输注靶向修饰的现货型慢病毒或mRNA-脂质纳米颗粒（LNP），直接在患者循环血液中特异性转导重编程内源性T细胞，彻底摆脱耗时昂贵的体外细胞制备壁垒。","url":"/technology/in-vivo-car-t-generation/","verified":"2026-11-22"}